SCHEMBL23908523

SCHEMBL23908523

CCCC(=O)Nc1ccc(-c2cnc3cc(Cl)ccc3n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP7 Q9BQF6 3/20 0.63
CASP3 P42574 2/20 0.63
SENP8 Q96LD8 2/20 0.63
SENP6 Q9GZR1 2/20 0.63
ADORA3 P0DMS8 3/20 0.55
TP53 P04637 2/20 0.51
FBP1 P09467 1/20 0.49
PARP3 Q9Y6F1 1/20 0.48
RAB9A P51151 6/20 0.47
NPC1 O15118 3/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
GAA P10253 1/20 0.45
GFER P55789 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23908580 0.99 SENP7 (0.62) SENP7CASP3SENP8SENP6ADORA3
SCHEMBL21793867 0.85 SENP7 (0.64) SENP7CASP3SENP8SENP6ADORA3
SCHEMBL30723192 0.84 KMT2A (0.56) SENP7CASP3ADORA3TP53RAB9A
SCHEMBL21793861 0.84 KMT2A (0.56) SENP7CASP3ADORA3TP53RAB9A
SCHEMBL21793707 0.84 SENP7 (0.62) SENP7CASP3SENP8SENP6ADORA3
SCHEMBL21793874 0.81 SENP7 (0.58) SENP7CASP3TP53RAB9ANPC1
SCHEMBL30723187 0.81 SENP7 (0.58) SENP7CASP3TP53RAB9ANPC1
SCHEMBL21793711 0.81 SENP7 (0.57) SENP7CASP3TP53RAB9ANPC1
SCHEMBL30723199 0.81 SENP7 (0.57) SENP7CASP3TP53RAB9ANPC1
SCHEMBL21793933 0.79 NPC1 (0.49) TP53RAB9ANPC1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations ALBERT EINSTEIN COLLEGE OF MEDICINE 2024-05-16 US disclosed
US-11834424-B2 Compounds useful as chaperone-mediated autophagy modulators ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2023-12-05 US disclosed
EP-4212516-A1 2-PHENYL-6-HALO-QUINOXALINE DERIVATIVES AS CHAPERONE-MEDIATED AUTOPHAGY (CMA) MODULATORS FOR THE TREATMENT OF PARKINGSON'S DISEASE Albert Einstein College of Medicine (US) 2023-07-19 EP disclosed
US-20210317095-A1 COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS ALBERT EINSTEIN COLLEGE OF MEDICINE 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834424-B2 Compounds useful as chaperone-mediated autophagy modulators SQSTM1, HSPA5, ATG7 SENP7 3099/4885CASP3 2834/4885SENP8 2657/4885
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations SQSTM1, MCL1, HSPA2 SENP7 1775/4885CASP3 1753/4885SENP8 1370/4885
US-20210317095-A1 COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS SQSTM1, HSPA5, ATG7 SENP7 3099/4885CASP3 2834/4885SENP8 2657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.